38 results about "Extended Release Formulations" patented technology

The disclosure provides a dosing regimen utilizing an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

The present invention relates to a bilayer tablet comprising extended-release formulation having metformin or a pharmaceutically acceptable salt thereof and at least one cellulose derivates as binder and immediate release formulation having sitagliptin or a pharmaceutically acceptable salt thereof and at least one antioxidant. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process of preparing the bilayer tablet.

Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and / or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and / or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic / methacrylic / ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

Disclosed are high dose gastric retentive, extended-release lithium salt dosage forms suitable for once a day administration.

The present invention relates to a tablet formulation comprising a core tablet having metformin and at least one matrix agent and a coating solution having sitagliptin surrounding the core tablet and a film coating wherein the coating solution further comprises at least one antioxidant and at least one coating agent. Further, the present invention provides a method for the preparation of said composition.

The disclosure provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.

Disclosed herein include methods, compositions, and kits suitable for use in treating fibromyalgia. In some embodiments, the method comprises the administration of a composition comprising ketamine, norketamine and a pharmaceutically acceptable salt thereof. In some embodiments, the composition is an extended-release formulation, such as an implant.

The invention relates to extended-release formulations comprising substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5'-monophosphate- activated protein kinase (AMPK). The invention further relates to methods of treating a condition comprising administering an extended-release formulation comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.

Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.

The disclosure provides, inter alia, formulations for drug delivery, such as extended release of peptide therapeutics.

The present invention relates to a bilayer tablet comprising extended-release formulation having metformin or a pharmaceutically acceptable salt thereof and at least one cellulose derivates as binder and immediate release formulation having sitagliptin or a pharmaceutically acceptable salt thereof and at least one antioxidant. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process of preparing the bilayer tablet.

The invention relates to extended-release formulations comprising substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5′-monophosphate-activated protein kinase (AMPK). The invention further relates to methods of treating a condition comprising administering an extended-release formulation comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.

Compositions for the extended release of one or more cannabinoids, in which the compositions comprise a population of particles. Each particle may comprise the one or more cannabinoids, one or more drug-releasing agents, one or more surfactants, and a core. The core may comprise a porous bead. The one or more cannabinoids may comprise Δ9-tetrahydrocannabinol, cannabidiol, or a combination thereof.

The disclosure provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

The invention provides an oral extended release formulation for the treatment of treatment-resistant depression, treatment-resistant anxiety, and phobia.

Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.

To provide stable and bioavailable extended-release formulations and dosage forms of BMS-986165, which is a highly selective inhibitor of Tyk2, for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.SOLUTION: A dosage form for extended release of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (BMS-986165) is provided, the dosage form comprising (i) an inner phase comprising a spray-dried dispersion of BMS-986165 in a polymer matrix; and (ii) an outer phase comprising a release-controlling polymer.SELECTED DRAWING: None

Provided are solid amorphous 6-(cyclopropanamido)-4-((2-methoxy-3-(1-methyl-1H-1, 2, 4-triazol-3-yl) phenyl) amino)-N-(methyl-d3) pyridazine-3-carboxamide (Formula (I); the present invention relates to stable and bioavailable extended release formulations and dosage forms of dispersions (e.g., spray-dried dispersions) of liposomes (e.g., BMS-986165) for use in the treatment of autoimmune and autoinflammatory diseases such as Inflammatory Bowel Disease (IBD) and psoriasis. # imgabs0 #

This invention relates generally to injectable drug delivery systems and methods of preparing same, and in particular to drug delivery systems comprising biodegradable polymeric nanogel formulations that form a depot (gel) in the body once injected, and can release therapeutic agents with enhanced extended-release times in the subject being treated. The polymer matrix drug delivery systems of the subject invention are comprised of a biodegradable polymer, a solvent or a combination of solvents, an alkylphenol, and therapeutic agents such as insulin, tetrandrine, other small molecule drugs (preferably hydrophobic drugs) to treat a variety of diseases including diabetes and hearing loss. A preferred alkylphenol is meta cresol which has demonstrated importance for dissolving and stabilizing the therapeutic agents, and forming gels with better shape and controlled drug release after injection.

Described herein are implantable devices comprising living cells and an extended release formulation of a glucocorticoid.

The present disclosure encompasses methods and compositions for extended-release formulations for treating ophthalmic conditions. These formulations comprise a pharmaceutical agent, a cationic polymer, a non-ionic polymer, and a pharmaceutical carrier and are essentially preservative free. The formulations provided herein are particularly useful for sustained and controlled release of drugs and have low side effects.

The disclosure provides a dosing regimen utilizing an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

The invention provides an oral extended release formulation for the treatment of treatment-resistant depression, treatment-resistant anxiety, and phobia.

The present invention relates to a tablet formulation comprising a core tablet having metformin and microcrystalline cellulose, at least one matrix agent and a coating solution having sitagliptin surrounding the core tablet and a film coating wherein the coating solution further comprises at least one antioxidant and at least one coating agent. Further, the present invention provides a method for the preparation of said composition.

Disclosed are high dose gastric retentive, extended-release lithium salt dosage forms suitable for once a day administration.

Provided are solid amorphous 6-(cyclopropanamido)-4-((2-methoxy-3-(1-methyl-1H-1, 2, 4-triazol-3-yl) phenyl) amino)-N-(methyl-d3) pyridazine-3-carboxamide (Formula (I); the present invention relates to stable and bioavailable extended release formulations and dosage forms of dispersions (e.g., spray-dried dispersions) of liposomes (e.g., BMS-986165) for use in the treatment of autoimmune and autoinflammatory diseases such as Inflammatory Bowel Disease (IBD) and psoriasis. # imgabs0 #